

## TAT-NSF222 Fusion Peptide

<b>Cat. No.:</b>	HY-P4110
<b>Molecular Formula:</b>	C <sub>187</sub> H <sub>301</sub> N <sub>67</sub> O <sub>47</sub>
<b>Molecular Weight:</b>	4239.81
<b>Sequence:</b>	Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly-Gly-Gly-Leu-Asp-Lys-Glu-Phe-Asn-Ser-Ile-Phe-Arg-Arg-Ala-Phe-Ala-Ser-Arg-Val-Phe-Pro-Pro-Glu
<b>Sequence Shortening:</b>	YGRKKRRQRRRGGLDKEFNSIFRRAFASRVFPPE
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

#### Description

TAT-NSF222 Fusion Peptide is a fusion polypeptide with two domains, a TAT domain, which enters cells through macropinocytosis, and an NSF domain that inhibits N-ethylmaleimide-sensitive factor (NSF). TAT-NSF222 Fusion Peptide is an exocytosis inhibitor<sup>[1]</sup>.

### REFERENCES

- [1]. Munekazu Yamakuchi, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1301-6.
- [2]. Munekazu Yamakuchi, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1301-6.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA